当前时间:2022/1/26 13:45:55
当前位置:首页 >> 最新医学研究

DNA标记能指示卵巢癌治疗是否成功

发布时间:2012/4/29 8:01:26    发布者:中国中西医结合医学会    点击量:910

美国北岸医疗集团和范因斯坦医学研究院的研究人员和医生发现,血液能帮助确定卵巢癌患者的最佳治疗计划。具体地说,DNA中一个称为microRNA的遗传标记可指示出卵巢癌患者是否有一个良性或癌性肿瘤,表明患者在肿瘤手术后是否受益于化疗。这些数据来自3月31日至4月3日举行的美国癌症研究协会年会上的报告。

 

据估计,美国今年有22280例新卵巢癌病例,其中15500例死亡。由于缺乏适当的筛查,大量卵巢癌患者被诊断时已是III期(癌症的倒数第二个时期,最具破坏性的时期),此时70%的患者将5年死于此癌症。

microRNA能帮助预测卵巢癌患者的最佳治疗方案,这些患者很可能处于卵巢癌III期,这一发现给患者带来了巨大希望。现在,能告知卵巢癌III期患者手术后的化疗是否会取得与卵巢癌I期卵巢癌患者相类似的成功效果。这个信息给了他们疾病可以治愈的希望,尽管是在晚期诊断出来。同时也给了他们进行化疗的必需力量,因为化疗是获得治愈所必需的一种颇具侵略性与毒性的疗法。

已发现几个microRNA与各种癌症相关。在化疗期间,microRNA-195增加40倍,microRNA-16增加80倍。这些改变可以解释一些卵巢癌患者为何出现化疗副作用,为什么其他患者可治愈癌症和其他患者为何需要继续化疗以持续带癌存活。

了解化疗治疗全程中的microRNA变化将帮助我们更好地了解卵巢癌,如何最有效治疗卵巢癌患者,已确定的遗传标记使患者能进行个性化治疗,以便最大化益处,最小化副作用。此外,还能使研究人员卵巢癌患者开发新治疗方法。(生物谷bioon.com)

 

DNA Marker Indicates If Ovarian Cancer Treatment Will Be Successful, Study Suggests

sciencedaily/Apr. 3, 2012

Researchers and doctors at the North Shore-LIJ Health System and the Feinstein Institute for Medical Research discovered that blood can help determine the best treatment plan for patients with ovarian cancer. More specifically, a genetic marker embedded in deoxyribonucleic acid (DNA), called microRNA, indicates if a patient with ovarian cancer has a benign or cancerous tumor, and that she will benefit from chemotherapy after surgery on the tumor.

This data was presented at the American Association for Cancer Research (AACR) Annual Meeting which was held from March 31- April 4 in Chicago, IL.

It is estimated that there will be 22,280 new cases and 15,500 deaths this year from ovarian cancer in the United States. Due to lack of adequate screening, the majority of patients with ovarian cancer are diagnosed at stage III (the second-to-last and most devastating stage of cancer), when 70 percent of these patients will die of their disease within 5 years.

"The discovery that microRNAs can help predict the best treatment plan for women with ovarian cancer, who are most likely at stage III of the disease, offers them enormous hope," noted Iuliana Shapira, MD, director of the Cancer Genetics Program at the North Shore-LIJ Health System's Monter Cancer Center. "We can now inform patients at stage III ovarian cancer, if they will have success with chemotherapy following surgery, similar to patients who are at stage 1 disease. This information gives them hope that their disease is curable despite being diagnosed at an 'advanced stage.' It also gives them the strength necessary to undergo chemotherapy, which is a very invasive and toxic therapy necessary to obtain the cure."

Several microRNAs have been found to have links with various types of cancer. The research conducted at the North Shore-LIJ Health System and the Feinstein Institute for Medical Research found that microRNA-195 increased 40 fold during chemotherapy and microRNA-16 increased 80 fold during chemotherapy. These changes may explain why some patients with ovarian cancer have side effects of chemotherapy, why others become cured of cancer as a result of chemotherapy, and why others need ongoing chemotherapy to continue living with the cancer.

"Understanding the changes in microRNA throughout chemotherapy treatment helps us better understand ovarian cancer and how best to treat patients who have this disease," said Annette Lee, PhD, associate investigator at the Feinstein Institute. "The genetic markers we identified allow patients to individualize their own therapy in order to have maximum benefit and minimal side effects. In addition, this knowledge will help researchers develop new treatments for patients with ovarian cancer."

Dr. Shapira adds that, "We applied for a government grant and hope to receive the funds needed to validate these markers allow result in women receiving therapies that are more personalized and match their genetic makeup."